Keytruda Market Size & Share Analysis - Growth Trends and Forecasts (2024 - 2029)

Keytruda Market Analysis

The Keytruda Market size is estimated at USD 27.80 billion in 2024, and is expected to reach USD 32.10 billion by 2029, at a CAGR of 2.94% during the forecast period (2024-2029).

Keytruda (pembrolizumab), a monoclonal antibody, targets the programmed death-1 (PD-1) receptor. It plays a pivotal role in cancer immunotherapy, empowering the body's immune system to identify and eliminate cancer cells. As an immune checkpoint inhibitor, Keytruda obstructs the PD-1/PD-L1 interaction, bolstering T-cell responses against tumors. Key factors fueling the growth and evolution of the Keytruda market include the rising adoption of immunotherapy, increasing cancer incidences, and a surge in regulatory approvals for diverse indications.

The increasing global prevalence of various cancers, particularly lung cancer, melanoma, and head and neck cancers, is driving the demand for immune checkpoint inhibitors like Keytruda. The rising prevalence of cancer has driven demand for innovative treatments such as Keytruda, which is a significant driver for the Keytruda market.

For instance, the rising incidence of cancer and the urgent demand for more effective and precise treatment options are primary catalysts for market expansion. Further, data from the Red Espanola de Registros de Cancer in 2023 revealed that Spain diagnosed approximately 31,282 lung cancer cases, up from 29,188 in 2022. Various therapies are commonly employed to combat lung cancer. Consequently, the uptick in lung cancer diagnoses plays a pivotal role in propelling the market's growth. Additionally, in February 2023, Cancer Research United Kingdom projected that new cancer diagnoses in the UK would surge from roughly 420,000 cases during 2023-2025 to an estimated 506,000 cases by 2038-2040.

Moreover, data from the Australia Institute of Health and Welfare in August 2023 indicated that Australia recorded approximately 154,000 cancer diagnoses, with projections suggesting a rise to 200,000 by 2033. Thus, the escalating cancer diagnoses are poised to fuel the market's growth during the forecast period.

In addition, the increasing focus on immunotherapy as a treatment for various cancers has positioned pembrolizumab (Keytruda) as a pivotal drug in oncology. A landmark study, KEYNOTE-564, has showcased pembrolizumab's efficacy in treating clear-cell renal cell carcinoma (RCC), the most common form of kidney cancer. Participants with earlier-stage kidney cancer who had surgery were assigned to receive pembrolizumab or a placebo for a year. The trial results demonstrated a remarkable 40% reduction in the risk of death for those on pembrolizumab, with a 4-year survival rate of 91%, compared to 86% in the placebo group. The growing preference for immunotherapy post-surgery for high-risk patients will likely drive the adoption of Keytruda, amplifying market growth.

Moreover, the market growth of Keytruda is bolstered by its multiple FDA approvals and ongoing clinical trials. For example, in June 2024, Keytruda secured its 40th FDA nod, this time for advanced or recurrent endometrial cancer in tandem with chemotherapy. This milestone stems from the Phase 3 NRG-GY018 trial's success, showcasing a 70% dip in disease progression risk when Keytruda teamed up with chemotherapy. With this latest endorsement, Keytruda's repertoire now spans approvals for melanoma, non-small cell lung cancer (NSCLC), liver, colorectal, and triple-negative breast cancer, further propelling its market adoption.

Thus, the rising prevalence of cancer, increasing regulatory approvals, and growing demand for immunotherapy support the market’s growth in the next five years. However, the emergence of competitors and the high cost of Keytruda may restrain market growth.

Keytruda Market Trends

Stomach Cancer Segment is Expected to Witness Significant Growth Over the Forecast Period

Keytruda Industry Segmentation

Keytruda (pembrolizumab) is an immunotherapy drug that blocks the PD-1 receptor, enhancing the immune system’s ability to detect and destroy cancer cells. It is widely used to treat various cancers, including melanoma, lung, and gastric.

The Keytruda market is segmented into cancer type, therapy type, distributional channel, and geography. By cancer type, the market is segmented into non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), stomach cancer, and others (colorectal cancer, urothelial carcinoma, among others). By therapy type, the market is segmented into monotherapy, combination therapy, adjuvant therapy, and neoadjuvant therapy. By distribution channel, the market is segmented into hospital pharmacies and specialty pharmacies. By geography, the market is segmented into North America, Europe, Asia-Pacific, South America, and Middle East and Africa. The report also offers the market size and forecasts for 17 countries across the region. For each segment, the market sizing and forecasts have been done on the basis of value (USD).